← All trials
NCT04365270
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2019
- Primary completion
- Jun 1, 2020
- Completion date
- Jul 30, 2020
- First posted
- Apr 28, 2020
- Last posted
- Apr 28, 2020
- Enrollment
- 40
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityStudy director
- Ain Shams UniversityStudy chair
- British University In EgyptOverall official - principal investigator
- British University In EgyptReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.